Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 06 2022 - 4:30PM
Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the
“Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical
company focused on the discovery, development, and
commercialization of targeted therapies for women’s cancers, today
announced that Shane Kovacs, Chief Operating and Financial Officer,
will participate in a fireside chat at the H.C. Wainwright 24th
Annual Global Investment Conference on Wednesday, September 14,
2022, at 2:30 p.m. ET (11:30 a.m. PT).
A live webcast of the fireside chat and the
corporate presentation may be accessed under the Investors &
Media section of Olema’s website (www.olema.com) and will be
archived for 14 days.
About Olema Oncology
Olema Oncology is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of targeted therapies for women’s cancers.
Olema’s lead product candidate, OP-1250, is an orally available
small molecule with combined activity as both a complete estrogen
receptor (ER) antagonist (CERAN) and a selective ER degrader
(SERD). It is currently being evaluated as a single agent in an
ongoing Phase 1/2 clinical trial, and in Phase 1b combination with
palbociclib, in patients with recurrent, locally advanced or
metastatic ER-positive (ER+), human epidermal growth factor
receptor 2-negative (HER2-) breast cancer. Olema is headquartered
in San Francisco and has operations in Cambridge,
Massachusetts.
IR Contact:Shane Kovacs, COO and
CFOir@olema.com
Media Contact:Ignacio Guerrero-Ros, Ph.D., Russo
Partners646-942-5604ignacio.guerrero-ros@russopartnersllc.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jul 2023 to Jul 2024